SCHEMBL3853375

SCHEMBL3853375

CCOC(=O)c1c(O)c(-c2ccc(Cl)cc2)nn(Cc2ccccc2Cl)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
GAA P10253 2/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
EGLN3 Q9H6Z9 1/20 0.45
PDE4B Q07343 3/20 0.43
SLC16A3 O15427 3/20 0.43
SLC16A1 P53985 3/20 0.43
MCTS1 Q9ULC4 3/20 0.43
PDE4A P27815 2/20 0.43
PDE4C Q08493 2/20 0.43
PDE4D Q08499 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP19A1 P11511 1/20 0.43
KDM4E B2RXH2 3/20 0.43
F2RL3 Q96RI0 1/20 0.42
NLRP3 Q96P20 1/20 0.42
HPGD P15428 2/20 0.42
CYP1A2 P05177 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3849224 0.94 ALDH1A1 (0.50) ALDH1A1GAALMNAMAPTPDE4B
SCHEMBL3849543 0.92 ALDH1A1 (0.47) ALDH1A1GAALMNAMAPTPDE4B
SCHEMBL3846803 0.91 MAPT (0.46) ALDH1A1GAALMNAMAPTPDE4B
SCHEMBL3847266 0.91 EGLN3 (0.51) ALDH1A1GAALMNAMAPTEGLN3
SCHEMBL3848738 0.87 ALDH1A1 (0.46) ALDH1A1GAALMNAMAPTPDE4B
SCHEMBL3847510 0.87 EGLN3 (0.55) ALDH1A1GAALMNAEGLN3PDE4B
SCHEMBL3856473 0.85 SLC16A3 (0.50) ALDH1A1SLC16A3SLC16A1MCTS1KDM4E
SCHEMBL3849089 0.84 ALDH1A1 (0.53) ALDH1A1GAALMNAMAPTPDE4B
SCHEMBL3847935 0.83 ALDH1A1 (0.46) ALDH1A1GAALMNAMAPTPDE4B
SCHEMBL3853108 0.83 SLC16A3 (0.45) ALDH1A1GAALMNAMAPTPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2889289-A1 Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors GlaxoSmithKline LLC (US) 2015-07-01 EP disclosed
US-RE44613-E1 N-substituted glycine derivatives: hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-11-26 US disclosed
CN-101626685-B N-substituted glycine derivatives: hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2013-03-13 CN disclosed
US-7608621-B2 Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production SMITHKLINE BEECHAM, CORP. (US) 2009-10-27 US disclosed
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors EGLN2, EGLN3, HIF1AN ALDH1A1 564/4885GAA 225/4885LMNA 2802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.